ETNB is expected to report earnings to fall 45.22% to -76 cents per share on March 19
Q4'24
Est.
$-0.76
Q3'24
Missed
by $0.77
Q2'24
Beat
by $0.08
Q1'24
Missed
by $0.08
Q4'23
Missed
by $0.01
The last earnings report on November 08 showed earnings per share of -138 cents, missing the estimate of -62 cents. With 88.32K shares outstanding, the current market capitalization sits at 939.48M.
a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases